ClinicalTrials.gg
CompletedNCT07391709Updated Feb 6, 2026

Investigation of the Protective Effect of Alpha Lipoic Acid on Ischemic Reperfusion Damage in Ischemic Priapism in Rats

An interventional study of Ischemic priapism + reperfusion and Ischemic priapism + reperfusion + ALA in Priapism and Reperfusion Injury, sponsored by Trabzon Kanuni Education and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 10 Weeks to 16 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Trabzon Kanuni Education and Research Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Feb 2024, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
10 Weeks to 16 Weeks
Sex
Male
01

Study summary

The condition known in medical terminology as 'Priapism' refers to the state of erection in the male sexual organ persisting partially or completely for more than 4 hours without sexual stimulation or orgasm. This 'prolonged and painful erection' is generally observed in young adults, although it can occur in all age groups, including the neonatal period. There are three main types: ischaemic (restricted blood flow), non-ischaemic (unrestricted blood flow), and recurrent 'prolonged and painful erection'. This disorder is believed to develop as a result of malfunctions in the mechanism that causes the male sexual organ to lose its erection (detumescence of the penis). Although the return of blood flow (reperfusion) to the tissue following the termination of 'long and painful erection' is necessary to preserve this structure that has been deprived of blood for a period of time, the return of blood flow itself initiates a mechanistic process that causes damage due to restricted blood flow and the return of blood flow to the tissue.

Currently, there is no effective and safe medical treatment used to prevent tissue damage caused by ischaemia-reperfusion injury in the treatment of 'long and painful erection'. Currently, there is no effective and safe medical treatment used in the treatment of 'long and painful erection' to prevent tissue damage resulting from ischaemia-reperfusion injury. Alpha-lipoic acid is an antioxidant found in some foods and naturally produced in the body. In this study, a model of 'long and painful erection' will be created in a total of 18 rats divided into 6 groups, and the possible biochemical and histopathological protective effects of alpha-lipoic acid against this condition will be investigated.

Read the detailed description

Priapism refers to a prolonged erection lasting more than four hours without any sexual stimulation, caused by a dysfunction of the mechanisms that regulate penile swelling, rigidity, and relaxation . Pathophysiologically, there are three main types of priapism: ischaemic, non-ischaemic, and recurrent (stuttering). Ischemic (veno-occlusive, low-flow) priapism is the most common type. Sickle cell anaemia, vasoactive drug use, haematological dyscrasias, heparin therapy, haemodialysis, malignancies (local or metastatic), hyperlipidaemia parenteral nutrition therapy, and trauma are among the many conditions that can cause priapism. Acute ischaemic priapism represents a medical emergency and may subsequently lead to erectile dysfunction (ED) . Ischemia-reperfusion (I/R) injury occurs with the resolution of priapism. Although reperfusion is a necessary mechanism for the preservation of ischaemic tissue, reperfusion itself initiates a pathophysiological process that causes injury. With I/R injury, neutrophils, inflammatory cytokines, and adhesion molecules with increased thrombogenicity are activated, and free oxygen radicals develop with massive intracellular Ca release . Oxidative stress damages the cell membrane and has harmful effects on the tissue, leading to permanent cellular injury. Alpha-lipoic acid (ALA) is an 8-carbon molecule first isolated from bovine liver in 1950 that can cross the blood-brain barrier. It may also be referred to as 1,2-dithiolane-3-pentanoic acid or thioctic acid . Alpha-lipoic acid (ALA) is a natural substance found in certain foods and also synthesised in the body. It is abundant in animal and plant tissues rich in mitochondrial complexes. Among plants, spinach, broccoli, and tomatoes contain the highest amounts of lipoic acid. In animal tissues, it is most abundant in the kidneys, heart, and liver. ALA is an enzymatic cofactor involved in glucose and lipid metabolism and regulates gene transcription. ALA also acts as an antioxidant because it not only improves internal antioxidant systems but also restores them and supports their production or cellular accessibility. It also effectively removes heavy metals responsible for oxidative stress from the bloodstream. ALA's most unique feature compared to other antioxidants is that it reacts as both a lipid and water-soluble compound . Pharmacologically, ALA improves glycaemic control and diabetes mellitus-related polyneuropathies; it also effectively reduces toxicities associated with heavy metal poisoning. As an antioxidant, ALA directly eliminates free radicals, chelates transition metal ions, increases cytosolic glutathione and vitamin C levels, and prevents toxicities associated with their depletion . It is used in preclinical studies and clinically in AIDS, renal lithiasis, ethanol intoxication, cerebral ischaemia, stroke, Parkinson's disease, skin inflammation, diabetic neuropathy, radiation damage, and cataract disease . This study will examine the efficacy of ALA in alleviating reperfusion injury in rat models of ischaemic priapism using biochemical and histopathological methods.

Literature review:

Publications on the subject published in PubMed, ClinicalKey, EAU, AUA Guide, National Thesis Centre, and Google Scholar were reviewed. Publications on ischaemic priapism within priapism were reviewed. These publications included a detailed examination of the pathophysiology, aetiology, interventions and treatments of priapism, and experimentally induced ischaemic priapism models. Publications containing biochemical properties related to alpha-lipoic acid and experimental studies used for treatment purposes were examined. Publications containing biomarker and histopathological examinations of serum and tissue samples examined in animal experimental models with induced ischaemia-reperfusion were reviewed.

Objective: The aim of this experimental study is to investigate the possible effects of alpha-lipoic acid on this condition biochemically and histopathologically by creating a 'long and painful erection' model in rats.

02

Conditions studied

  • Priapism
  • Reperfusion Injury

Browse trials for

Keywords

  • Priapism
  • Alpha Lipoic Acid
  • Ischemia-Reperfusion Injury
  • Antioxidant
  • Rat
03

In context

Reperfusion Injury

260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.

This study's enrollment of 18 is below the median of 60 across 212 interventional studies indexed under Reperfusion Injury.

Browse Reperfusion Injury studies →

Lead sponsor

Trabzon Kanuni Education and Research Hospital is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Weeks to 16 Weeks
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male Sprague-Dawley rats weighing 350-400 g.

Exclusion criteria

Exclusion Criteria:

  • Animals with congenital anomalies, active infection, or systemic disease.
  • Animals that died before completion of the experimental protocol.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • No intervention
    Control group

    Healthy rats with no induction of ischemic priapism or reperfusion. No pharmacological treatment was administered.

  • Experimental
    Ischemic priapism + reperfusion

    Ischemic priapism was induced by applying a tourniquet to the base of the penis for 4 hours, followed by reperfusion. No antioxidant or pharmacological treatment was given.

    Procedure: Ischemic priapism + reperfusion

  • Experimental
    Ischemic priapism + reperfusion + ALA

    Ischemic priapism was induced by a 4-hour penile base tourniquet followed by reperfusion. Alpha-lipoic acid (ALA) was administered intraperitoneally at a dose of 100 mg/kg, 30 minutes before reperfusion.

    Procedure: Ischemic priapism + reperfusion + ALA · Drug: Ischemic priapism + reperfusion + ALA

Interventions

  • ProcedureIschemic priapism + reperfusion

    Ischemic priapism was induced by applying a tourniquet to the base of the penis for 4 hours, followed by reperfusion.

    Also known as: Penile ischemia-reperfusion injury model, Penile tourniquet-induced ischemic priapism, Experimental ischemic priapism model

  • ProcedureIschemic priapism + reperfusion + ALA

    Ischemic priapism was induced by applying a tourniquet to the base of the penis for 4 hours, followed by reperfusion.

    Also known as: Penile tourniquet-induced ischemic priapism, Experimental ischemic priapism model, Penile ischemia-reperfusion injury model

  • DrugIschemic priapism + reperfusion + ALA

    Drug page: Thioctic AcidStudies of Thioctic AcidThioctic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Alpha-lipoic acid was administered intraperitoneally at a dose of 100 mg/kg, 30 minutes before reperfusion.

    Also known as: ALA, α-Lipoic acid

06

What researchers measure

Primary outcomes

  1. Change in serum total antioxidant status (TAS) measured by Erel spectrophotometric assay

    Serum total antioxidant status (TAS) will be measured using the Erel spectrophotometric assay.Unit of Measure mmol Trolox equivalent/L

    Time frame: 7 days after reperfusion

  2. Change in serum total oxidant status (TOS) measured by Erel spectrophotometric assay

    Serum total oxidant status (TOS) will be measured using the Erel spectrophotometric assay.Unit of Measure µmol H₂O₂ equivalent/L

    Time frame: 7 days after reperfusion

  3. Change in serum glutathione peroxidase (GPx) activity measured by spectrophotometric enzyme activity assay

    Serum glutathione peroxidase (GPx) activity will be measured using a spectrophotometric enzyme activity assay.Unit of Measure U/L

    Time frame: 7 days after reperfusion

  4. Change in serum malondialdehyde (MDA) concentration measured by ELISA

    Serum malondialdehyde (MDA) concentration will be measured using a commercial ELISA kit.Unit of Measure ng/mL

    Time frame: 7 days after reperfusion

  5. Change in serum ischemia-modified albumin (IMA) concentration measured by ELISA

    Serum ischemia-modified albumin (IMA) concentration will be measured using a commercial ELISA kit.Unit of Measure U/mL

    Time frame: 7 days after reperfusion

Secondary outcomes

  1. Change in serum tumor necrosis factor-alpha (TNF-α) concentration measured by ELISA

    Serum tumor necrosis factor-alpha (TNF-α) concentration will be measured using a commercial ELISA kit.Unit of Measure pg/mL

    Time frame: 7 days after reperfusion

  2. Change in penile tissue tumor necrosis factor-alpha (TNF-α) concentration measured by ELISA

    Penile tissue tumor necrosis factor-alpha (TNF-α) concentration will be measured using a commercial ELISA kit and normalized to tissue protein content.Unit of Measure pg/mg protein

    Time frame: 7 days after reperfusion

Other outcomes

  1. Change in GRP78 protein expression in penile tissue measured by immunohistochemistry

    GRP78 protein expression in penile tissue will be assessed using immunohistochemical semi-quantitative scoring.Unit of Measure Semi-quantitative score

    Time frame: 7 days after reperfusion

  2. Change in CHOP protein expression in penile tissue measured by immunohistochemistry

    CHOP protein expression in penile tissue will be assessed using immunohistochemical semi-quantitative scoring.Unit of Measure Semi-quantitative score

    Time frame: 7 days after reperfusion

07

Study locations

1 site
  • Karadeniz Technical University Experimental Animal Research Center
    Trabzon, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2024, 5 months.

Of 46 non-industry interventional studies with no phase under Reperfusion Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 5 months is below that.

Counting every sponsor, half of 50 studies reached it within 26 months; a quarter within 15 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Feb 6, 2026
StartActual
Feb 10, 2024
Primary completionActual
Jul 10, 2024
CompletionActual
Sep 10, 2024
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07391709
Lead sponsor
Trabzon Kanuni Education and Research Hospital
Responsible party
İbrahim Sibal (doctor, Trabzon Kanuni Education and Research Hospital) — Principal investigator
First posted
Feb 6, 2026
Start date
Feb 10, 2024
Primary completion
Jul 10, 2024
Completion
Sep 10, 2024
Last update
Feb 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thioctic Acid

Start the discussion